Atlas Trials

An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself

Clinical trial NCT02320058 · COMPLETED

Trial details

NCT number
NCT02320058
Sponsor
Bristol-Myers Squibb
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Melanoma
Start date
2015-03-05
Primary completion
2020-09-08
Enrollment
119

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.